Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of...
Clinical Trial
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences...
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue...
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy...
RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform...
Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain
– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come...
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology...
Alkeus Pharmaceuticals to Present Corporate Update at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of...
Illumina and PREMIA partner to expand clinical access to CGP in Asia
TAIPEI, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a...
MannKind Provides Business Updates and 2026 Growth Drivers
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated...
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08,...
Recludix Pharma Bolsters Scientific Advisory Board with Acclaimed Leaders in the Fields of Rheumatology, Dermatology and JAK/STAT Biology
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors...
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
- Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such...
AskBio Announces FDA Acceptance of Investigational New Drug (IND) Application for AB-1009 Gene Therapy for Treatment of Late-Onset Pompe Disease (LOPD)
Durham, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- AB-1009 program advances to Phase 1/Phase 2; clinical trial initiated in the...
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA...
RESTEM Provides Corporate Update and Announces Strategic Priorities for 2026
MIAMI, Jan. 08, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed...
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”)...
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support clinician-assessed efficacy outcomes in...
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem...
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small...